Dysregulated NF-kappa B signaling is critical for lymphomagenesis, however, the expression and clinical relevance of NF-kappa B subunit p50 in diffuse large B-cell lymphoma have not been evaluated. In this study, we analyzed the prognostic significance and gene expression signatures of p50 nuclear expression as a surrogate for p50 activation in 465 patients with de novo diffuse large B-cell lymphoma. We found that p50(+) nuclear expression, observed in 34.6% of diffuse large B-cell lymphoma, predominantly composed of activated B-cell-like subtype, was an independent adverse prognostic factor in patients with activated B-cell-like diffuse large B-cell lymphoma. It was also an adverse prognostic factor in patients with wild-type TP53 independent of the activated B-cell-like and germinal center B-cell-like subtypes, even though p50 activation correlated with significantly lower levels of Myc, PI3K, phospho-AKT, and CXCR4 expression and less frequent BCL2 translocations. In contrast, in germinal center B-cell-like diffuse large B-cell lymphoma patients with TP53 mutations, p50(+) nuclear expression correlated with significantly better clinical outcomes, and decreased p53, Bcl-2, and Myc expression. Gene expression profiling revealed multiple signaling pathways potentially upstream the p50 activation through either canonical or noncanonical NF-kappa B pathways, and suggested that immune suppression, including that by the immune checkpoint TIM-3 and that through leukocyte immunoglobulin-like receptors, but not antiapoptosis and proliferation, may underlie the observed poorer survival rates associated with p50(+) nuclear expression in diffuse large B-cell lymphoma. In conclusion, these data show that p50 is important as a unique mechanism of R-CHOP-resistance in activated B-cell-like diffuse large B-cell lymphoma and in patients without TP53 mutations. The results also provide insights into the regulation and function of p50 in diffuse large B-cell lymphoma and its cross talk with the p53 pathway with important therapeutic implications.
基金:
National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI); National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01CA138688, R01CA187415, 1RC1CA146299]; University of Texas MD Anderson Cancer Center Institutional Research Grant Award; MD Anderson Lymphoma Specialized Programs of Research Excellence (SPORE) Research Development Program Award; MD Anderson Myeloma SPORE Research Developmental Program Award; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81672686, 81372883, 81001052]; Natural Science Foundation of Guangdong Province, ChinaNational Natural Science Foundation of Guangdong Province [2015A030313020]; Science and Technology Planning Project of Guangdong Province, China [2011B031800222]; Young Talents Key Project of Sun Yat-sen University [2015ykzd13]; MD Anderson Cancer Center Support Grant [CA016672]; Sister Institution Network Fund of MD Anderson Cancer Center; [P50CA136411]; [P50CA142509]
语种:
外文
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类|2 区医学
小类|1 区病理学
最新[2025]版:
大类|1 区医学
小类|1 区病理学
第一作者:
第一作者机构:[1]Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Dept Med Oncol,Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China;[2]Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, 1515 Holcombe Blvd, Houston, TX 77030 USA;
通讯作者:
通讯机构:[2]Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, 1515 Holcombe Blvd, Houston, TX 77030 USA;[8]Univ Texas Sch Med, Grad Sch Biomed Sci, Houston, TX USA
推荐引用方式(GB/T 7714):
Cai Qingqing,Tu Meifeng,Xu-Monette Zijun Y.,et al.NF-kappa B p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53[J].MODERN PATHOLOGY.2017,30(6):854-876.doi:10.1038/modpathol.2017.5.
APA:
Cai, Qingqing,Tu, Meifeng,Xu-Monette, Zijun Y.,Sun, Ruifang,Manyam, Ganiraju C....&Young, Ken H..(2017).NF-kappa B p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53.MODERN PATHOLOGY,30,(6)
MLA:
Cai, Qingqing,et al."NF-kappa B p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53".MODERN PATHOLOGY 30..6(2017):854-876